Cirio advises Sprint Bioscience in connection with a licence agreement

Cirio has advised Sprint Bioscience AB (publ) in connection with a licence agreement with Deciphera Pharmaceuticals.

Sprint Bioscience AB (publ) and U.S. pharmaceutical company Deciphera Pharmaceuticals have entered into a licence agreement for global exclusive rights to Sprint Bioscience’s Vps34 program in cancer treatment. Under the agreement, Sprint Bioscience will obtain 4 million USD in upfront payment and the agreement has an aggregate potential value of 277 million USD.

In addition, Sprint Bioscience is entitled to mid-single digit through low double digit royalty percentages from sales of a future pharmaceutical from the program, if a pharmaceutical is approved.

Cirio has advised Sprint Bioscience in connection with the transaction through Anders Burén (Life Sciences).